INTRODUCTION
Bleeding and hemostatic defects are common complications of uremia. Multiple abnormalities in laboratory tests of hemostasis have been reported [2] [3] [4] . These abnormalities include defects in platelet aggregation, platelet retention, platelet factor 3 availability, and prostaglandin synthesis. These defects may contribute to the frequently observed prolongations of the bleeding time found in uremic patients [5] . The exact mechanism underlying these abnormalities remains obscure. Not surprisingly, therapy is also problematic in many cases. Dialysis has been the standard therapy for uremic bleeding, although at times it is ineffective [6, 7] . Recently, cryoprecipitate and deamino-8-D-arginine vasopressin (DDAVP) have emerged as therapeutic alternatives [1, [8] [9] [10] .
While cryoprecipitate is widely used for hemostatic alterations or bleeding secondary to renal failure, very little data exist to support this approach. Janson and associates reported seven patients in whom the bleeding time shortened and bleeding complications were reduced after cryoprecipitate therapy [ 1 ] . To our knowledge, there have been only two other case reports on the use of cryoprecipitate in uremia [1 1,12] . While many hematologists believe that cryoprecipitate works only in some uremic patients, there are no reported data contradicting the initial uniformly positive findings. We performed a retrospective review of uremic patients who received cryoprecipitate therapy in our institution in order to determine whether laboratory abnormalities or bleeding were consistently ameliorated by this therapy, as suggested in the original report.
MATERIALS AND METHODS

Patients
The medical records of 82 consecutive patients discharged from Strong Memorial Hospital, Rochester, New York, between April 1984 and January 1987 with a diagnosis of renal failure (acute or chronic), who had received cryoprecipitate therapy were reviewed. For unambiguous evaluation of efficacy from the standpoint of this study, we felt that the following information or situtations were required: (1) platelet count > 100,000/,ul so that patients whose bleeding time abnormality or bleeding might be on the basis of thrombocytopenia would not be included, (2) normal prothrombin time (PT) and/or activated partial thromboplastin time (PTT) so that patients whose bleeding was on the basis of deficiencies of coagulation factors measured in these assays would not be included, and (3) prolonged template bleeding time with at least one post-infusion bleeding time. Five of 82 patients met all these criteria (four males and one female). Many of the patients were not evaluable simply because no post-infusion bleeding time had been performed.
All five patients had an elevated template bleeding time > 15 minutes (normal, four to nine minutes) prior to therapy, and an elevated blood urea nitrogen (BUN) ranging from 41 to 99 mg/dl. None had taken platelet function-altering drugs. Three patients (patients 2, 3, and 5) were dialyzed within 24 hours prior to their cryoprecipitate infusions, and two patients received additional pre-infusion blood transfusions (patient 3 received fresh frozen plasma; patient 4 received red blood cells). The abnormal bleeding times were measured after administration of these components. None received platelet transfusions. Normal ranges: BUN, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] mg/dl; Creatinine, 0.5-1.0 mg/dl; PTT, 25.0-37.0 sec; PT, 9.5-12.5 sec
RESULTS
The effects of cryoprecipitate therapy on bleeding time and clinical outcome for the five patients are summarized in Table 2 . Patients Who Responded Satisfactorily to Cryoprecipitate Therapy Two patients (patients 1 and 3) achieved normal bleeding times after cryoprecipitate infusion. In the bleeding patient (patient 3), this laboratory improvement was accompanied by cessation of bleeding from a subclavian vein dialysis catheter site. This bleeding gradually subsided over a four-day period, during which cryoprecipitate therapy (10 U daily or 0.95 U/10 kg) had failed to correct the bleeding time initially, improved to 12.0 minutes after the third dose, and normalized 16 hours after the last dose (fourth day) of cryoprecipitate therapy.
The asymptomatic patient (patient 1) received two preoperative cryoprecipitate doses that were six hours apart and consisted of 10 U (1.6 U/I0 kg) each. The bleeding time corrected to 8.5 minutes, five hours after the second dose. Open renal biopsy was performed without complications. An apy. Figure 1 displays the clinical course of this patient in terms of therapy and response. DISCUSSION Janson and colleagues reported seven patients, all of whom had improvement in their bleeding time by four hours after cryoprecipitate treatment [1] . The nadir value of bleeding time occurred one to 12 hours after infusion. Consonant with the anecdotal, contrary experience of many, only one of our five patients responded in a comparable fashion (patient 1). One other patient had a beneficial effect of cryoprecipitate therapy (patient 3). This recipient showed a gradual decrease in bleeding time over 36 hours with multiple doses of cryoprecipitate. A normal bleeding time of eight minutes was finally obtained 16 hours after the fourth and last cryoprecipitate dose. Concomitantly there was a gradual decrease in bleeding from a subclavian vein catheter site. These data support the clinical usefulness of cryoprecipitate, although with a different time course of correction than that previously reported, and with one patient requiring several doses prior to improvement.
Three patients, similar to those previously reported, had no apparent response to cryoprecipitate therapy. Cryoprecipitate did not correct the bleeding time in patients 2, 4, and 5, nor did it ameliorate bleeding complications in patients 4 and 5. Patient 4 is of special interest in that his severe hematuria from a renal biopsy was not reduced after a single dose of cryoprecipitate therapy but did improve after two doses of DDAVP, with a bleeding time shortened to eight minutes. While no post-cryoprecipitate infusion bleeding time was obtained before DDAVP was started, the normal bleeding time occurred two days after the infusion of cryoprecipitate and therefore was most likely due to DDAVP rather than to the cryoprecipitate. The efficacy of DDAVP in the setting of uremia has been described [8, 9] .
While our case reports are limited by lack of a standardized treatment protocol, some conclusions are possible. Contrary to the original report of uniform success, correction of bleeding time within a few hours after a single dose of cryoprecipitate was the exception rather than the rule in these five patients. Some patients may respond only after multiple doses of cryoprecipitate. For practical purposes, some patients do not respond at all, when urgent clinical interventions are required. The time course of correction of bleeding time in patients responding to cryoprecipitate therapy appears to be much more variable than that seen in the originally reported seven patients. At least one and occasionally more post-infusion bleeding times are necessary in order to identify these patients.
The apparent efficacy of DDAVP in patient 4, in whom cryoprecipitate was ineffective, is interesting in that it suggests that the mechanisms of action of DDAVP and cryoprecipitate may be different. In addition, patient 4 received multiple red cell transfusions. Several investigators have found a negative correlation between bleeding time and hematocrit in uremic patients [14, 15] . Abnormal bleeding times have improved, but not necessarily normalized with red cell transfusion [14, 15] or erythropoietin therapy [ 16] in anemic patients with renal failure. The relative contribution of red cell transfusion and DDAVP to the normalized bleeding time in this patient is impossible to quantitate, but the rapid clinical response to DDAVP suggests that this was the primary therapeutic agent. We, and most others, would favor use of DDAVP in most patients as initial treatment, due to its lower risk and possibly more rapid onset of action. The risks associated with cryoprecipitate include post-transfusion hepatitis, HIV infection, allergic or, rarely, anaphylactic reactions, and serologic incompatibility due to red cell isoagglutinins. Cryoprecipitate should be reserved for those failing to respond to DDAVP, for whom DDAVP is contraindicated, and perhaps when massive bleeding or emergent operative intervention is required.
Our review also demonstrates that cryoprecipitate is frequently used without evaluation of whether it has decreased the patient's risk of bleeding (i.e., correcting the bleeding time). This use may be a necessary approach in some urgent situations; however, in many instances where cryoprecipitate was given to reduce the risk of bleeding, it appeared that the procedure would be done whether improvement occurred or not. Having decided that a hemostatic defect constitutes sufficient danger to expose the patient to the risks of homologous transfusion, it seems inconsistent not to determine that the desired benefit has been accomplished. Our data do suggest that cryoprecipitate use in uremic patients in our institution is probably providing no hemostatic improvement in a substantial number of patients, and that failure to measure the bleeding time post-transfusion leaves the physician unaware of its lack of efficacy.
